BR112016021011A8 - composição tópica e usos de um composto - Google Patents

composição tópica e usos de um composto

Info

Publication number
BR112016021011A8
BR112016021011A8 BR112016021011A BR112016021011A BR112016021011A8 BR 112016021011 A8 BR112016021011 A8 BR 112016021011A8 BR 112016021011 A BR112016021011 A BR 112016021011A BR 112016021011 A BR112016021011 A BR 112016021011A BR 112016021011 A8 BR112016021011 A8 BR 112016021011A8
Authority
BR
Brazil
Prior art keywords
topical composition
compound
hyperhidrosis
mild
excessive sweating
Prior art date
Application number
BR112016021011A
Other languages
English (en)
Other versions
BR112016021011A2 (pt
BR112016021011B1 (pt
Inventor
Angulo David
J Koleng John
S Bodor Nicholas
Original Assignee
Bodor Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bodor Laboratories Inc filed Critical Bodor Laboratories Inc
Publication of BR112016021011A2 publication Critical patent/BR112016021011A2/pt
Publication of BR112016021011A8 publication Critical patent/BR112016021011A8/pt
Publication of BR112016021011B1 publication Critical patent/BR112016021011B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants

Abstract

composição tópica anidra. a presente invenção se refere às formulações tópicas que compreende os glicopirrolatos leves que são úteis para o tratamento de condições de transpiração excessiva em indivíduos, tais como os humanos que sofrem de hiperidrose. de preferência, pelo menos, um agente anticolinérgico leve é fornecido em uma quantidade ou concentração eficaz de uma formulação anidra que pode inibir a transpiração excessiva resultante a partir de uma condição tal como a hiperidrose.
BR112016021011-5A 2014-03-13 2015-03-12 Composição de gel anidro tópica e usos de um composto BR112016021011B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461952505P 2014-03-13 2014-03-13
US61/952,505 2014-03-13
US14/285,488 US20150259283A1 (en) 2014-03-13 2014-05-22 Formulation for soft anticholinergic analogs
US14/285,488 2014-05-22
PCT/US2015/020253 WO2015138776A1 (en) 2014-03-13 2015-03-12 Formulation for soft anticholinergic analogs

Publications (3)

Publication Number Publication Date
BR112016021011A2 BR112016021011A2 (pt) 2017-08-15
BR112016021011A8 true BR112016021011A8 (pt) 2021-07-20
BR112016021011B1 BR112016021011B1 (pt) 2022-12-13

Family

ID=54068191

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016021011-5A BR112016021011B1 (pt) 2014-03-13 2015-03-12 Composição de gel anidro tópica e usos de um composto

Country Status (20)

Country Link
US (8) US20150259283A1 (pt)
EP (1) EP3116498B1 (pt)
JP (5) JP6293919B2 (pt)
KR (3) KR102586868B1 (pt)
CN (3) CN110917124B (pt)
AU (2) AU2015229243B2 (pt)
BR (1) BR112016021011B1 (pt)
CA (1) CA2941649C (pt)
DK (2) DK3116498T3 (pt)
ES (1) ES2710292T3 (pt)
HU (1) HUE041868T2 (pt)
IL (1) IL247571B (pt)
MX (1) MX369129B (pt)
MY (1) MY183531A (pt)
PH (1) PH12016501732A1 (pt)
PL (1) PL3116498T3 (pt)
PT (2) PT3116498T (pt)
SG (1) SG11201607480SA (pt)
WO (1) WO2015138776A1 (pt)
ZA (1) ZA201607071B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008531732A (ja) * 2005-03-03 2008-08-14 ルバンス セラピュティックス インク． ボツリヌス毒素の局所塗布及び経皮送達のための組成物及び方法
CA2920110C (en) 2013-08-08 2022-05-31 Novan, Inc. Compositions and kits including a nitric oxide releasing compound and a hydrogel
US20150259283A1 (en) 2014-03-13 2015-09-17 Brickell Biotech, Inc. Formulation for soft anticholinergic analogs
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
CN108137612A (zh) 2015-07-21 2018-06-08 博多尔实验仪器公司 软性抗胆碱能药类似物的制剂
TWI719046B (zh) * 2016-07-21 2021-02-21 美商波德實驗股份有限公司 軟性抗膽鹼類似物之製劑
US11381304B2 (en) * 2017-08-30 2022-07-05 Iridium Satellite Llc Satellite communications with multiple classes of terrestrial terminal devices
KR20220011671A (ko) * 2019-05-23 2022-01-28 가켄 세이야쿠 가부시키가이샤 소프피로늄 브롬화물 결정체 및 그의 제조방법
CA3174550A1 (en) 2020-03-03 2021-09-10 Kaken Pharmaceutical Co., Ltd. Medicament containing sofpironium bromide
TW202146010A (zh) 2020-03-03 2021-12-16 日商科研製藥股份有限公司 原發性腋窩多汗症的治療方法及其醫藥
KR102655121B1 (ko) 2021-09-17 2024-04-08 한국식품연구원 락토바실러스 사케이 k040706 균주 검출용 프라이머 세트 및 이의 용도
US11807604B1 (en) * 2022-02-16 2023-11-07 Miralogx Llc Pharmaceutical compounds, pharmaceutical compositions, and methods of treating asthma and other disorders
WO2024026412A1 (en) * 2022-07-28 2024-02-01 Tff Pharmaceuticals, Inc. Thin film freezing methods and compositions formulated from dispersed active agents
KR102611847B1 (ko) * 2023-03-27 2023-12-12 주식회사 이플라스크 무스카린 수용체 길항 활성을 갖는 신규한 피롤리디늄 화합물 및 이의 용도

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK149832C (da) * 1981-07-17 1987-05-18 Riemann Claus Antiperspirantpraeparat bestaaende af to komponenter
CA2014633C (en) * 1989-06-02 2000-07-18 Andrew D. Mccrea Stable anhydrous compositions for topical delivery of active materials
US5292530A (en) * 1991-06-02 1994-03-08 Helene Curtis, Inc. Stable anhydrous topically-active composition and suspending agent therefor
US5232689A (en) * 1990-12-21 1993-08-03 Dow Corning Corporation Translucent antiperspirant compositions
US5895644A (en) * 1997-11-20 1999-04-20 Colgate-Palmolive Company Clear antiperspirant stick with dibenzylidene sorbitol and guar and process of making same
US6433003B1 (en) 1999-04-23 2002-08-13 Arthur M. Bobrove Method for treating hyperhidrosis in mammals
US20030064040A1 (en) * 2001-09-26 2003-04-03 Lukacsko Alison B. Compositions and methods for inhibiting eccrine perspiration in humans
US8252316B2 (en) * 2002-05-03 2012-08-28 Purepharm Inc. Method of topically applying glycopyrrolate solution using absorbent pad to reduce sweating
US7087560B2 (en) * 2004-10-25 2006-08-08 Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. Personal care composition with salts of dihydroxypropyltri(C1-C3 alkyl) ammonium monosubstituted polyols
US20060088496A1 (en) * 2004-10-25 2006-04-27 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Personal care compositions with salts of hydroxypropyl trialkylammonium substituted mono-saccharide
GB0428416D0 (en) * 2004-12-24 2005-02-02 Novartis Ag Organic compounds
GB0428418D0 (en) * 2004-12-24 2005-02-02 Novartis Ag Organic compounds
BRPI0519481A2 (pt) * 2004-12-27 2009-02-03 Beiersdorf Ag glicopirrolato em preparaÇÕes cosmÉticas
EP1951186A4 (en) * 2005-10-19 2009-11-04 Menni Menashe Zinger METHODS FOR TREATING HYPERHIDROSIS
AU2006315657B2 (en) * 2005-11-10 2011-12-01 Shell Internationale Research Maatschappij B.V. Soft anticholinergic esters
US7399861B2 (en) 2005-11-10 2008-07-15 Bodor Nicholas S Soft anticholinergic esters
AU2006201878A1 (en) * 2006-03-13 2007-09-27 Foamix Ltd Foamable composition for hyperhidrosis
JP5371235B2 (ja) * 2006-12-06 2013-12-18 ロート製薬株式会社 皮膚外用剤
US10265265B2 (en) * 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
CA2702830C (en) * 2007-10-18 2017-02-28 Stiefel Research Australia Pty Ltd Topical glycopyrrolate formulations
US20100137357A1 (en) * 2008-11-26 2010-06-03 Koleng John J Compositions and methods for hyperhidrosis
US20140037713A1 (en) * 2012-08-03 2014-02-06 Antares Pharma Ipl, Ag Transdermal compositions for anti-cholinergic agents
TR201808040T4 (tr) 2013-03-15 2018-06-21 Bodor Laboratories Inc Hiperhidrozun tedavisine yönelik yumuşak antikolinerjik esterler.
WO2015138700A1 (en) 2014-03-13 2015-09-17 Bodor Laboratories, Inc. Use of selected anticholinergic zwitterions
US20150259283A1 (en) 2014-03-13 2015-09-17 Brickell Biotech, Inc. Formulation for soft anticholinergic analogs

Also Published As

Publication number Publication date
US20170020845A1 (en) 2017-01-26
AU2019257421A1 (en) 2019-11-21
SG11201607480SA (en) 2016-10-28
CN110420167B (zh) 2023-02-17
US20150259283A1 (en) 2015-09-17
EP3116498B1 (en) 2018-12-12
US11034652B2 (en) 2021-06-15
KR102586868B1 (ko) 2023-10-11
KR102433868B1 (ko) 2022-08-19
CA2941649C (en) 2021-03-02
US10961191B2 (en) 2021-03-30
JP6756763B2 (ja) 2020-09-16
US10947192B2 (en) 2021-03-16
JP2020079321A (ja) 2020-05-28
AU2015229243A1 (en) 2016-10-20
MX2016011529A (es) 2016-12-07
AU2019257421B2 (en) 2021-10-21
DK3325487T3 (da) 2021-08-02
KR20220119517A (ko) 2022-08-29
CA2941649A1 (en) 2015-09-17
IL247571B (en) 2020-03-31
JP6461267B2 (ja) 2019-01-30
KR20230145522A (ko) 2023-10-17
PH12016501732B1 (en) 2017-02-06
US20200113869A1 (en) 2020-04-16
EP3116498A4 (en) 2017-11-08
US20210078946A1 (en) 2021-03-18
CN110917124B (zh) 2023-06-20
AU2015229243B2 (en) 2019-11-21
JP6293919B2 (ja) 2018-03-14
JP6762047B2 (ja) 2020-09-30
JP2017507970A (ja) 2017-03-23
MY183531A (en) 2021-02-25
CN110917124A (zh) 2020-03-27
CN110420167A (zh) 2019-11-08
PT3325487T (pt) 2021-07-29
US20150320722A1 (en) 2015-11-12
US11084788B2 (en) 2021-08-10
CN106456603A (zh) 2017-02-22
US20210087142A1 (en) 2021-03-25
DK3116498T3 (en) 2019-03-11
IL247571A0 (en) 2016-11-30
BR112016021011A2 (pt) 2017-08-15
KR20160133492A (ko) 2016-11-22
WO2015138776A1 (en) 2015-09-17
BR112016021011B1 (pt) 2022-12-13
US20200093791A1 (en) 2020-03-26
CN106456603B (zh) 2020-01-10
US20210198195A1 (en) 2021-07-01
ZA201607071B (en) 2018-12-19
PL3116498T3 (pl) 2019-05-31
JP2019189650A (ja) 2019-10-31
PT3116498T (pt) 2019-02-11
HUE041868T2 (hu) 2019-05-28
ES2710292T3 (es) 2019-04-24
JP2017214429A (ja) 2017-12-07
PH12016501732A1 (en) 2017-02-06
JP2018115203A (ja) 2018-07-26
EP3116498A1 (en) 2017-01-18
MX369129B (es) 2019-10-30

Similar Documents

Publication Publication Date Title
BR112016021011A8 (pt) composição tópica e usos de um composto
BR112019001081A2 (pt) composição tópica, utilização de uma composição, métodos para o tratamento da hiperidrose em um indivíduo, composição e composição para a utilização
CO2019004137A2 (es) 1,2,4–triazolonas 2,4,5–trisustituidas
BR122021018243A8 (pt) Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável
CL2016000188A1 (es) Composiciones de arní de serpinc1 y métodos de uso de las mismas
BR112017012327A2 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
BR112015032541A2 (pt) conservação de composições para cuidados pessoais
DOP2016000253A (es) Nuevos compuestos
BR112016007462A2 (pt) fitonutrientes anti-inflamatórios para uso no tratamento ou prevenção de sinovite
PH12018500184A1 (en) Formulation for soft anticholinergic analogs
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
BR112015027440A2 (pt) DERIVADO DE [1,2,4]TRIAZOL[4,3-a]PIRIDINA, MÉTODO DE PREPA-RAÇÃO OU APLICAÇÃO MÉDICA DO DERIVADO
BR112018006314A2 (pt) composto da fórmula, composição, uso de composto da fórmula, método de combate a fungos fitopatogênicos e semente revestida
DOP2016000007A (es) Pirazolpiridinas sustituidas
ECSP20023626A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
BR112018013170A2 (pt) formulação cosmética segura, agente dermatologicamente seguro, e, métodos para reduzir a quantidade de sais com base em alumínio em formulações que reduzem perspiração e de desodorantes ou para substituir ditos sais, para reduzir ingredientes antimicróbicos em formulações que reduzem perspiração e de desodorantes ou para substituir ditos ingredientes e para fabricar um desodorante cosmético ou formulação?
MX2016015896A (es) Composiciones que contienen azufre polimerico y usos de estas.
BR112017023144A2 (pt) composições cosméticas compreendendo ésteres de estolídeo e usos para o tratamento capilar
BR112016029996A2 (pt) utilização cosmética, composição e método cosmético para tratar os odores corporais
CR20160432A (es) Inhibidores de las vías de señalización de wnt
BR112017022032A2 (pt) métodos para tratamento de transtornos de armazenamento lisossômico
GB2564990A (en) Topical compositions for neuropathic pain
BR112018010616A2 (pt) compostos inibidores seletivos de mmp-12
BR112017014823A2 (pt) composto antimicrobiano, composição farmacêutica, uso de composto antimicrobiano e método de tratamento de pacientes
MX2019000136A (es) Composiciones de acido cromoglicico para tratamiento de dermatitis.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/03/2015, OBSERVADAS AS CONDICOES LEGAIS